38 research outputs found

    LAPAROSCOPIC SURGERY IN TREATMENT OF ENDOMETRIAL CANCER (RESULTS OF 7-YEAR CLINICAL EXPERIENCE AT THE N.N. PETROV NATIONAL MEDICAL RESEARCH ONCOLOGY CENTER)

    Get PDF
    Introduction. The main method of treatment of endometrial cancer, the most common oncological disease, is surgery. Introduction of high-tech operations into gynecological practice promoted active use of laparoscopy in treatment of malignant tumors of the endometrium.Objective. To evaluate effectiveness of video endoscopic surgery in treatment of endometrial cancer.Materials and methods. In the period from 2010 to 2016, 1127 patients with endometrial cancer underwent surgery using video endoscopic complex with high resolution cameras at the N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia.Results.Β  Using video endoscopic technology, excision of the uterus with appendages was performed in 588 (52.3 %) patients, excision of the uterus with appendages and pelvic lymph node dissection was performed in 523 (46.4 %) patients including 16 (1.4 %) patients with serous and papillary serous forms of endometrial cancer who also underwent omentectomy. No intraoperative complications were observed. In the majority of patients, postoperative period was characterized by early activization, satisfactory intestinal peristalsis on day 1, minimal complications, absence of contraindications for adjuvant beam therapy.Conclusion. Video endoscopic technology is a modern method of surgical treatment allowing to perform the full scope of planned radical surgical intervention in patients with endometrial cancer irrespectively of age and concomitant disorders with minimal traumatization, risk of intraand postoperative complications as well as favorable and fast rehabilitation period

    The number of transmission channels through a single-molecule junction

    Full text link
    We calculate transmission eigenvalue distributions for Pt-benzene-Pt and Pt-butadiene-Pt junctions using realistic state-of-the-art many-body techniques. An effective field theory of interacting Ο€\pi-electrons is used to include screening and van der Waals interactions with the metal electrodes. We find that the number of dominant transmission channels in a molecular junction is equal to the degeneracy of the molecular orbital closest to the metal Fermi level.Comment: 9 pages, 8 figure

    ΠΠ•Π™Π ΠžΠ­ΠΠ”ΠžΠšΠ Π˜ΠΠΠ«Π• ОПУΠ₯ΠžΠ›Π˜ Π¨Π•Π™ΠšΠ˜ МАВКИ

    Get PDF
    The purpose of the study was to summarize the available data on etiology, diagnosis, clinical symptoms and signs as well as on various approaches to the treatment of neuroendocrine cervical tumors.Material and Methods. The relevant sources were searched in the PubMed and cochrane Library systems, and publications from 1980 to 2019 were analyzed, 53 of which were used to write this review. We also included 6 case reports from N.N. Petrov National Research Center of Oncology.Results. Neuroendocrine tumors (NETs) are extremely rare and aggressive malignancies of the female genital tract, among which NETs of the cervix are the most common. Due to the rarity of these tumors, there are currently no treatment standards based on prospective, well-planned clinical trials. For these reasons, NETs present a significant therapeutic challenge for clinicians. Case reports. Six patients ranged in age from 32 to 71 years, with a median age of 46 years, were diagnosed with large-cell neuroendocrine carcinoma (4 patients) and small-cell neuroendocrine carcinoma (2 patients). One patient with stage IIIA dropped out of the follow-up schedule. Out of 5 followed up patients, 2 patients with stage IIIA and IIB died of disease progression after 6 and 11 months, respectively. One patient with stage IB1 is in remission for 16 months. Two patients with stage IIB continue to receive primary treatment.Conclusion. Neuroendocrine carcinoma of the cervix is a rare variant of cervical cancer. The choice of treatment options is decided only by a multidisciplinary team of doctors, and further research is required. ЦСль исслСдования – ΠΎΠ±ΠΎΠ±Ρ‰Π΅Π½ΠΈΠ΅ ΠΈΠΌΠ΅ΡŽΡ‰ΠΈΡ…ΡΡ Π΄Π°Π½Π½Ρ‹Ρ… ΠΎΠ± особСнности этиологии ΠΈ диагностики, клиничСской ΠΊΠ°Ρ€Ρ‚ΠΈΠ½Π΅ ΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Π°Ρ… Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ нСйроэндокринных ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ шСйки ΠΌΠ°Ρ‚ΠΊΠΈ.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Поиск ΡΠΎΠΎΡ‚Π²Π΅Ρ‚ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΡ… источников производился Π² систСмах PubMed ΠΈ cochrane Library, Π°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π»ΠΈΡΡŒ ΠΏΡƒΠ±Π»ΠΈΠΊΠ°Ρ†ΠΈΠΈ с 1980 ΠΏΠΎ 2019 Π³., 53 ΠΈΠ· ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… Π±Ρ‹Π»ΠΈ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Ρ‹ для написания Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΎΠ±Π·ΠΎΡ€Π°. Π’Π°ΠΊΠΆΠ΅ Π² ΠΏΡƒΠ±Π»ΠΈΠΊΠ°Ρ†ΠΈΠΈ освСщСны 6 случаСв собствСнных наблюдСний Π² НМИЦ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Н.Н. ΠŸΠ΅Ρ‚Ρ€ΠΎΠ²Π°.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. НСйроэндокринныС ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ (НЭО) ΡΠ²Π»ΡΡŽΡ‚ΡΡ ΠΊΡ€Π°ΠΉΠ½Π΅ Ρ€Π΅Π΄ΠΊΠΈΠΌΠΈ ΠΈ агрСссивными злокачСствСнными новообразованиями Π½ΠΈΠΆΠ½Π΅Π³ΠΎ ТСнского ΠΏΠΎΠ»ΠΎΠ²ΠΎΠ³ΠΎ Ρ‚Ρ€Π°ΠΊΡ‚Π°, срСди ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… НЭО шСйки ΠΌΠ°Ρ‚ΠΊΠΈ Π²ΡΡ‚Ρ€Π΅Ρ‡Π°ΡŽΡ‚ΡΡ Ρ‡Π°Ρ‰Π΅ всСго. Из-Π·Π° рСдкости этих ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ Π² настоящСС врСмя ΠΎΡ‚ΡΡƒΡ‚ΡΡ‚Π²ΡƒΡŽΡ‚ стандарты ΠΏΠΎ Π»Π΅Ρ‡Π΅Π½ΠΈΡŽ, основанныС Π½Π° проспСктивных, Ρ…ΠΎΡ€ΠΎΡˆΠΎ спланированных клиничСских исслСдованиях. По этим ΠΏΡ€ΠΈΡ‡ΠΈΠ½Π°ΠΌ НЭО ΠΏΡ€Π΅Π΄ΡΡ‚Π°Π²Π»ΡΡŽΡ‚ собой Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΡƒΡŽ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΡƒ для клиницистов. По Π΄Π°Π½Π½Ρ‹ΠΌ собствСнных наблюдСний, Π² НМИЦ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Н.Н. ΠŸΠ΅Ρ‚Ρ€ΠΎΠ²Π° срСдний возраст ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠΊ (n=6) составил 46 Π»Π΅Ρ‚, возрастной Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½ 32–71 Π³ΠΎΠ΄; распрСдСлСниС ΠΏΠΎ гистотипу: крупноклСточная нСйроэндокринная ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ° – 4, мСлкоклСточная нСйроэндокринная ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ° – 2 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΊΠΈ. Одна ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΊΠ° с IIIA стадиСй Π²Ρ‹Π±Ρ‹Π»Π° ΠΈΠ· наблюдСния; ΠΈΠ· 5 прослСТСнных 2 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΊΠΈ с IIIA ΠΈ IIB стадиСй ΡƒΠΌΠ΅Ρ€Π»ΠΈ ΠΎΡ‚ прогрСссирования заболСвания Ρ‡Π΅Ρ€Π΅Π· 6 ΠΈ 11 мСс соотвСтствСнно, 1 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΊΠ° с IB1 стадиСй послС ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ лСчСния находится Π² рСмиссии 16 мСс. Π”Π²Π΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΊΠΈ со IIB стадиСй Π² настоящСС врСмя ΠΏΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠ°ΡŽΡ‚ ΠΏΠΎΠ»ΡƒΡ‡Π°Ρ‚ΡŒ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ΅ Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Основная клиничСская ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ° Π·Π°ΠΊΠ»ΡŽΡ‡Π°Π΅Ρ‚ΡΡ Π² Ρ€Π΅Π΄ΠΊΠΎΠΉ встрСчаСмости Π΄Π°Π½Π½ΠΎΠ³ΠΎ гистологичСского ΠΏΠΎΠ΄Ρ‚ΠΈΠΏΠ° ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ шСйки ΠΌΠ°Ρ‚ΠΊΠΈ. Π’Ρ‹Π±ΠΎΡ€ Ρ‚Π°ΠΊΡ‚ΠΈΠΊΠΈ лСчСния Ρ€Π΅ΡˆΠ°Π΅Ρ‚ΡΡ ΠΌΡƒΠ»ΡŒΡ‚ΠΈΠ΄ΠΈΡΡ†ΠΈΠΏΠ»ΠΈΠ½Π°Ρ€Π½ΠΎ ΠΈ Ρ‚Ρ€Π΅Π±ΡƒΠ΅Ρ‚ Π΄Π°Π»ΡŒΠ½Π΅ΠΉΡˆΠΈΡ… исслСдований.
    corecore